We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

BioAffinity Technologies Inc (BIAF) USD0.001

Sell:$2.65 Buy:$2.73 Change: $0.03 (1.12%)
Market closed |  Prices as at close on 26 July 2024 | Switch to live prices |
Sell:$2.65
Buy:$2.73
Change: $0.03 (1.12%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 July 2024 | Switch to live prices |
Sell:$2.65
Buy:$2.73
Change: $0.03 (1.12%)
Market closed |  Prices as at close on 26 July 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

bioAffinity Technologies, Inc. is a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatment. Its segments include Diagnostic Research and Development (R&D) and Laboratory Services. Its Diagnostic R&D segment includes research and development and clinical development on diagnostic tests. Its Laboratory services include all the operations of Village Oaks and PPLS, in addition to sales and marketing of CyPath Lung from bioAffinity. Its first product, CyPath Lung, addresses the need for noninvasive detection of early-stage lung cancer. The CyPath Lung test enables physicians to more confidently identify patients who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening.

Contact details

Address:
22211 West Interstate-10, Suite 1206
SAN ANTONIO
78257
United States
Telephone:
+1 (210) 6985334
Website:
https://bioaffinitytech.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BIAF
ISIN:
US09076W1099
Market cap:
$32.87 million
Shares in issue:
11.66 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Steven Girgenti
    Executive Chairman of the Board
  • Maria Zannes
    President, Chief Executive Officer, Founder, Director
  • Michael Dougherty
    Chief Financial Officer, Principal Accounting Officer, Vice President
  • Vivienne Rebel
    Executive Vice President, Chief Science and Medical Officer
  • Timothy Zannes
    Executive Vice President, General Counsel, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.